近日,亚盛医药自主研发的新型口服Bcl-2选择性抑制剂——利生妥®(通用名:利沙托克拉)在京东健康全网独家首发。京东健康将依托自身“新特药全网首发第一站”能力优势,全面提升这款新药的可及性,让更多患者从中获益。据了解,利生妥®可用于既往经过至少包含布鲁顿酪氨酸激酶(BTK)抑制剂在内的一种系统治疗的成人慢性淋巴细胞白血病/小淋巴细胞淋巴瘤(CLL/SLL)患者,是国内首个获批上市的国产原创Bcl-...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.